Stockreport

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer [Yahoo! Finance...

Agenus Inc.  (AGEN) 
Last agenus inc. earnings: 3/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: agenusbio.com/investors
PDF patients and long-term survival beyond 20 months in a subset of heavily pretreated patients Induction strategy linked to improvement in progression-free survival (PFS) [Read more]